Hyperphosphatemia of chronic kidney disease

Slides:



Advertisements
Similar presentations
Bone Disease in Renal Failure Dr Anne Kleinitz and Dr Cherelle Fitzclarence
Advertisements

Navdeep Tangri, Paul V.J. Komenda, Claudio Rigatto 
Volume 69, Issue 1, Pages (January 2006)
Volume 79, Pages S3-S8 (April 2011)
LDL cholesterol in CKD—to treat or not to treat?
Volume 67, Pages S1-S7 (June 2005)
Volume 73, Issue 1, Pages 3-5 (January 2008)
Volume 88, Issue 6, Pages (December 2015)
Sodium thiosulfate prevents vascular calcifications in uremic rats
Volume 90, Issue 3, Pages (September 2016)
Volume 83, Issue 5, Pages (May 2013)
Volume 93, Issue 1, Pages (January 2018)
FGF23 or PTH: which comes first in CKD ?
Pieter Evenepoel, Myles Wolf  Kidney International 
Volume 61, Issue 4, Pages (April 2002)
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients  G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
FGF23–parathyroid interaction: implications in chronic kidney disease
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets  David M. Spiegel, Kate Brady  Kidney.
Reassessment of the care of the patient with chronic kidney disease
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 91, Issue 5, Pages (May 2017)
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Volume 82, Issue 12, Pages (December 2012)
Volume 85, Issue 3, Pages (March 2014)
Vascular calcification is dependent on plasma levels of pyrophosphate
Volume 79, Pages S9-S13 (April 2011)
Volume 64, Issue 2, Pages (August 2003)
Volume 72, Issue 6, Pages (September 2007)
Volume 62, Issue 1, Pages (July 2002)
A new era in phosphate binder therapy: What are the options?
Volume 85, Issue 1, Pages (January 2014)
Volume 79, Pages S20-S23 (April 2011)
Volume 66, Pages S25-S32 (September 2004)
Veerle P. Persy, Marc D. McKee  Kidney International 
Volume 84, Issue 3, Pages (September 2013)
Use of vitamin D in chronic kidney disease patients
Junichiro J. Kazama, Masafumi Fukagawa  Kidney International 
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
LDL cholesterol in CKD—to treat or not to treat?
Bisphosphonate safety and efficacy in chronic kidney disease
Metabolic acidosis inhibits soft tissue calcification in uremic rats
Charles R. Nolan, Wajeh Y. Qunibi  Kidney International 
Volume 83, Issue 5, Pages (May 2013)
Volume 69, Issue 3, Pages (February 2006)
Volume 74, Issue 10, Pages (November 2008)
Volume 88, Issue 4, Pages (October 2015)
E. Neven, S. Dauwe, M.E. De Broe, P.C. D'Haese, V. Persy 
Volume 67, Pages S51-S58 (June 2005)
Role of vitamin D receptor activators on cardiovascular risk
Navdeep Tangri, Paul V.J. Komenda, Claudio Rigatto 
Volume 81, Issue 8, Pages (April 2012)
The hypothesis that bone turnover influences FGF23 secretion
Volume 84, Issue 4, Pages (October 2013)
Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.
Volume 75, Issue 9, Pages (May 2009)
Circadian regulation of renal function
On vascular calcification and plasma levels of pyrophosphate
Fibroblast growth factor 23: the making of a hormone
Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives  Keith A. Hruska, Suresh Mathew, Matthew.
Phosphate and the parathyroid
Latest findings in phosphate homeostasis
Volume 71, Issue 8, Pages (April 2007)
The emerging role of phosphate in vascular calcification
Volume 69, Issue 1, Pages (January 2006)
The ins and outs of phosphate homeostasis
Cell biological and physicochemical aspects of arterial calcification
O.M. Gutiérrez, T. Isakova, D.L. Andress, A. Levin, M. Wolf 
Sclerostin and DKK1: new players in renal bone and vascular disease
Presentation transcript:

Hyperphosphatemia of chronic kidney disease Keith A. Hruska, Suresh Mathew, Richard Lund, Ping Qiu, Raymond Pratt  Kidney International  Volume 74, Issue 2, Pages 148-157 (July 2008) DOI: 10.1038/ki.2008.130 Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 1 Phosphorus balance in normal physiology. The kidney is the main regulator of human phosphate homeostasis. In adulthood, exit from the exchangeable phosphorus pool into the skeleton (bone formation) is roughly equal to entry into the exchangeable pool due to bone resorption. The skeleton is a storage depot for Pi and contains 85% of the total body phosphorus. Kidney International 2008 74, 148-157DOI: (10.1038/ki.2008.130) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 2 Phosphorus homeostasis is lost in CKD due to failure of excretion. Despite reductions in the fraction of filtered phosphorus that is reabsorbed, eventually the filtered load becomes insufficient to maintain homeostasis and positive phosphorus balance ensues. Kidney disease decreases the exchangeable phosphorus pool size by inhibiting bone formation. The skeletal mineralization fronts at the sites of new bone formation are significant components of the exchangeable phosphorus pool. Positive phosphate balance is associated with establishment of heterotopic mineralization sites in soft-tissue organs and the vasculature. Exit from the exchangeable phosphorus pool into the vasculature is portrayed as a bidirectional process because we have been able to demonstrate that stopping the exit into the vasculature results in diminishment of established vascular calcification levels. Kidney International 2008 74, 148-157DOI: (10.1038/ki.2008.130) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 3 Regulation of phosphorus balance in CKD. Regulation of phosphorus homeostasis is complex. In CKD, a decrease in calcitriol production leads to a decrease in calcium absorption, hypocalcemia, and hyperparathyroidism. Hyperparathyroidism is one factor contributing to the decrease in the fraction of filtered phosphorus reabsorbed (decrease in the tubular reabsorption of phosphorus (TRP)). Additionally, high levels of FGF23 and hyperphosphatemia itself contribute to reducing the TRP. However, when kidney failure becomes too severe, hyperphosphatemia ensues. Kidney International 2008 74, 148-157DOI: (10.1038/ki.2008.130) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 4 Vascular calcification causes cardiac morbidity and mortality in CKD. Vascular calcification increases arterial stiffness, leading to an increase in pulse wave velocity and pulse pressure both of which contribute to development of cardiac ischemia, and left ventricular hypertrophy and cardiac failure. Kidney International 2008 74, 148-157DOI: (10.1038/ki.2008.130) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 5 Control of hyperphosphatemia in translational studies results in reduction of established vascular calcium levels. LDLR-/- mice on high-fat diets with CKD have established vascular calcification at 22 weeks (baseline), which increases in vehicle-treated animals killed at 28 weeks (veh). However, in animals treated with sevelamer carbonate (1 and 3% sev), aortic calcium levels were significantly reduced compared with baseline, as the hyperphosphatemia was controlled.28 Kidney International 2008 74, 148-157DOI: (10.1038/ki.2008.130) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 6 Schematic representation of the experimental scheme for in vitro studies demonstrating that high phosphorus level causes vascular calcification and osteoblastic gene expression. Human VSMCs derived from atherosclerotic aortas expressed increased levels of morphogens, specific transcription factors, and biomarkers of the osteoblast, and decreased levels of those corresponding to contractile human VSMCs. Yet the cells did not mineralize until media Pi was increased from 1 to 2mm. High level of Pi in the media stimulated osterix expression, and when osterix expression was diminished in the presence of high media Pi level, there was no mineralization.38 Kidney International 2008 74, 148-157DOI: (10.1038/ki.2008.130) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 7 Expression of osterix in the aortas of LDLR-/-, high-fat-fed mice. High-fat feeding had a small effect to increase aortic osterix expression in sham-operated animals (sham fat) compared with wild-type mice. Induction of CKD (CKD high fat) produced a several fold increase in osterix expression, which was eliminated by treatment with phosphate binders, in this case 1 or 3% LaCO3 added to the diet.38 Kidney International 2008 74, 148-157DOI: (10.1038/ki.2008.130) Copyright © 2008 International Society of Nephrology Terms and Conditions